gp-5

CGP-53153 is a steroidal inhibitor of 5 alpha-reductase (IC50s: 36 and 262 nM in rat and human prostatic tissue).

GP-515 HCl 是一种腺苷激酶抑制剂。在培养的大鼠心肌肌母细胞（RMMs）中，GP-515能够诱导血管内皮生长因子（VEGF）的表达。在严重缺氧（1% O(2)）条件下，GP-515（20 microM）对VEGF蛋白表达无影响，但在轻度缺氧环境中，可使VEGF表达增加27%。

iGP-5 is a cell-permeable mitochondrial sn-Glycerol 3-phosphate dehydrogenase (mGPDH) inhibitor.

CGP-54626 is a selective antagonist of the GABAB receptor (IC50 = 4 nM ).

CGP-59326 is an epidermal growth factor receptor (EGFR) antagonist, which is used in anti-cancer research.

The growth factors, platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF) play major roles in enhanced smooth muscle cells growth in rodent blood vessels after vascular injury. Tyrosine kinase inhibition has been shown to be effective in blocking tyrosine phosphorylation at the PDGF and bFGF receptors in cultured fibroblast and vascular smooth muscle cells which in turn inhibits their proliferation[1]. CGP 53716 is a specific PDGFR tyrosine kinase inhibitor on SMC (smooth muscle cell) proliferation and migration in vitro and in neointimal formationin vivo[3]. CGP 53716 inhibited serum-induced cell growth in RASMC (rat aortic smooth muscle cells). And it completely blocked PDGF-BB tyrosine receptor autophosphorylation in RASMC and 3T3 cells, PDGF-BB-induced phosphorylation of mitogen-activated protein kinase at 1 μM in RASMC and inhibited PDGF-BB-induced c-Fos protein expression at 1 μM in RASMC; consistent with inhibition of PDGF-BB-induced DNA synthesis. Further, CGP 53716 inhibited PDGF-BB-, bFGF- and EGF-induced DNA synthesis in a concentration-dependent manner in each cell line. And it showed a 2- to 4-fold selectivity for PDGF-BB-stimulated DNA synthesis over bFGF or EGF in RASMC or 3T3 cells[1]. CGP 53716 inhibited dose dependently tyrosine phosphorylation of both the known PDGFRs: the PDGFR-α and PDGFR-β. After rat carotid artery ballooning injuryin vivo, the migration of alpha-actin-positive cells on the luminal side of internal elastic lamina was decreased with 50 mg kg day of CGP 53716 from 38 ± 10 (control group) to 4 ± 2. Intima media ratio was inhibited by 40% after 14 days in the CGP 53716-treated group (P=0.028) after rat aortic denudation[3].

CGP-53437 is a novel HIV-1 protease inhibitor, also potently inhibiting major aspartyl peptidase 1 (May1), a secreted Cryptococcus neoformans protease.

Imatinib Mesylate (STI571 Mesylate) 是一种多靶点受体酪氨酸激酶抑制剂，可选择性抑制 BCR ABL、v-Abl、PDGFR、c-kit 等激酶活性，具有口服活性。Imatinib Mesylate 具有抗肿瘤活性，可用于治疗慢性粒细胞白血病。

CGP52411 是一种具有口服活性的 ATP 竞争性 EGFR 抑制剂（IC50：0.3 μM）。 CGP52411 阻止 Ca2+ 离子有毒流入神经元细胞，并显着抑制和逆转 β-淀粉样蛋白 Aβ42 原纤维聚集体的形成。 CGP52411 可用于阿尔茨海默病的研究。

Imatinib (STI571) 是一种多靶点受体酪氨酸激酶抑制剂，可选择性抑制 BCR ABL、v-Abl、PDGFR、c-kit 等激酶活性，具有口服活性。Imatinib 具有抗肿瘤活性，可用于治疗慢性粒细胞白血病。

Cyclic-di-GMP is a STING agonist and ubiquitous second messenger, which regulates the formation, motility and virulence of biofilms in various bacterial species.

GP531 is a second-generation adenosine regulating agent. It is pharmacologically silent under basal conditions but increases localized endogenous adenosine during ischemia.

NGP555 是 γ-分泌酶调节剂。

CGP55845 hydrochloride 是一种有效的选择性 GABAB 受体拮抗剂，IC50为 6 nM, 具有神经学研究的潜力。

CGP 53353 (DAPH-7) 是一种具有选择性和有效性的 PKC 抑制剂，对 PKCβII 和 PKCβI 有抑制作用。CGP-53353 能在 AoSMC 和 A10 细胞中对葡萄糖诱导的细胞增殖和 DNA 合成有抑制作用。CGP-53353 可用于研究动脉粥样硬化。

CGP 54626 hydrochloride is a GABAB receptor antagonist.

CGP 56999A is an antagonist of GABA(B) receptor, it enhances expression of brain-derived neurotrophic factor and attenuates dopamine depletion in the rat corpus striatum.

CGP 52608 is a selective ligand for RAR-associated orphan receptor alpha.

CGP 53820 is a pseudosymmetric inhibitor of HIV-1 Protease.

CGP 55802A is a novel photoaffinity ligand for in-situ labeling of NMDA receptors.

CGP 57813 is a lipophilic compound, which can be used as an inhibitor of HIV-1 protease.

CGP52432 是一种GABAB 受体拮抗剂，IC50值为 85 nM。

CGP 57380 (MNK1 Inhibitor) 是细胞渗透的吡唑-嘧啶类化合物，是一种具有选择性的Mnk1抑制剂，IC50值为 2.2 μM。

ToP-DNJ is a selective inhibitor of endoplasmic reticulum α-Glucosidase II, exhibiting antiflaviviral activity.